Longitude Capital — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Helicorehelicore.comJan 2025
Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone.
BiotechHealthtech
Co-investorsOrbiMedVersant VenturesWellington Management
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.